A Multicenter, Double-masked, Placebo-controlled, Efficacy and Safety Study of an Insulin-like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), in Patients With Active Thyroid Eye Disease
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Teprotumumab (Primary)
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
- Sponsors Horizon Pharma; River Vision Development Corp
- 10 Aug 2017 Status changed from active, no longer recruiting to completed.
- 08 May 2017 According to Horizon Pharma Media release, River Vision Development Corp is acquired by Horizon Pharma on May 2017
- 04 May 2017 Primary endpoint (Clinical Activity Score) has been met.